Cartesian Therapeutics(RNAC)
FREDERICK, MDBiotechnology
Focus: Cartesian Therapeutics is a public biotechnology company pioneering mRNA-engineered cell therapy, with a focused pipeline addressing autoimmune diseases and hematologic malignancies. The company operates at micro-cap scale with ~25–50 employees and is generating early commercial revenue.
Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
5-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Cartesian Therapeutics?
AI assessmentCartesian offers a high-upside, high-risk opportunity for early-stage biotech professionals willing to bet on a Phase 3 catalystand pioneering cell therapy modality, but limited scale and debt dependency mean job security is contingent on clinical success.
Why Work Here
- Phase 3 catalyst imminent: Descartes-08 myasthenia gravis topline data expected 1Q27 with BLA filing mid-2027, offering clear near-term clinical inflection.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$39M
Pipeline & Clinical Trials
Descartes-25
Multiple MyelomaClinical Trials (1)
NCT05113342Descartes-25 in Relapsed/Refractory Multiple Myeloma
Phase 1Help build intelligence for Cartesian Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.